Tomar o no tomar «decisiones en caliente» respecto al tratamiento de la infección por SARS-CoV-2

Author:

Abril López de Medrano V.,Merino de Lucas E.,Salavert Lletí M.

Publisher

Elsevier BV

Subject

General Medicine

Reference5 articles.

1. Trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19;Cao;N Engl J Med.,2020

2. Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection;Cheng;Clin Microbiol Rev.,2007

3. From SARS to MERS, thrusting coronaviruses into the spotlight;Song;Viruses.,2019

4. Efficacies of lopinavir/ritonavir and abidol in the treatment of novel coronavirus pneumonia;Jun;Chin J Infect Dis.,2020

5. Results from a single center, open label, randomized, and controlled trial conducted at Shanghai Public Health Clinical Center (SPHCC) of darunavir and cobicistat (DRV/c) in treating laboratory-confirmed 30 COVID-19 patients showed that DRV/c was not effective [consultado 6 Abr 2020]. Disponible en: https://www.jnj.com/lack-of-evidence-to-support-darunavir-based-hiv-treatments-for-coronavirus

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. COVID-19 y Argumentum ad ignorantiam o «no todo vale»;Revista Clínica Española;2020-10

2. COVID-19 and Argumentum ad ignorantiam or “not everything goes”;Revista Clínica Española (English Edition);2020-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3